COVID-19 Active Research Experience (CARE)

IQVIA

Status: Completed

Conditions: COVID-19

Study type: Observational

Funder types: Industry

Identifiers

NCT04368065

IQVIA_COVIDREGISTRY_2020

Details and patient eligibility

About

COVID-19 Active Research Experience (CARE) is an observational, direct-to-participant, web-based, longitudinal study of adults with COVID-19 or COVID-19 like illness or who were vaccinated against COVID-19 to better understand risk factors, symptoms, and treatments for COVID-19 illness and vaccine safety and effectiveness.

Full description

This is an observational, direct-to-participant, web-based, longitudinal study of adults with COVID-19 or COVID-19 like illness to better understand risk factors, symptoms, and treatments for COVID-19 illness and vaccine safety and effectiveness. Upon consent and enrollment, participants will complete an initial baseline survey reporting their demographics, relevant medical history, testing, vaccination, symptoms, use of prescription medications as well as use of supplements and other factors. The study follow-up period is 12 months. During the first month of follow-up participants will be invited to complete a symptom diary weekly to gauge symptom progression and severity and to provide updates on pharmaceutical and non-pharmaceutical interventions as well as healthcare encounters. Reporting will then reduce to monthly for Month 2 through 12.

Enrollment: 35,278 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult (18 years or older)
• Currently living in the US or UK
• Have regular access to a computer, smartphone or tablet and sufficient internet to support registry demands (note: this registry is designed to operate well even in regions with low bandwidth)
• Willing and able to provide informed consent
• Willing and able to follow the procedures of the study

Participants must also meet at least one of the following conditions:

• Have COVID-19 or COVID-19 like symptoms
• Received a COVID-19 vaccine
• Potential exposure to COVID-19

Exclusion criteria

• Unable to provide informed consent
• Unable to perform the requested study tasks and unable or unwilling to assign a proxy informant to complete the tasks

Trial design